Grant ID CP130023
Awarded On February 19, 2014
Title Novel Ceramide-modulating Therapeutics for Cancer Use
Program Product Development Research
Award Mechanism Company Formation
Institution/Organization CerRx, Inc.
Principal Investigator/Program Director Richard Love
Cancer Sites Lymphoma
Contracted Amount $6,000,000
Lay Summary

CerRx is developing drugs to trick cancer cells into overproducing toxic waxes, called ceramides. When the ceramides increase to a certain level, cancer cells die. CerRx has a pipeline of such drugs, including fenretinide and safingol, which work synergistically against many cancer types in laboratory testing. Human testing already shows fenretinide eliminates the cancers of some patients with relapsed lymphomas.

CerRx needs funding to advance these drugs to market, specifically for the following clinical trials to be conducted in Texas-based consortia: 1) a larger trial of fenretinide in advanced Peripheral T-cell lymphoma, 2) a larger trial in advanced Cutaneous T-cell lymphoma, and 3) a t...

Read More